RA Capital affiliates report 18.75M Sana Biotechnology shares (NASDAQ: SANA)
RA Capital Management and its affiliated entities have reported a beneficial ownership of 18,750,000 shares of Sana Biotechnology (NASDAQ: SANA) common stock, representing 6.3% of the class. This disclosure was made in a Schedule 13G filing, indicating a passive investment. The percentage calculation is based on 278,291,590 outstanding shares as of April 30, 2026, plus an additional 21,607,878 shares issued through an at-the-market offering by May 14, 2026.
InvestingPro Fair Value spotted Sana Biotech overvaluation early By Investing.com
InvestingPro's Fair Value analysis accurately identified Sana Biotechnology (NASDAQ:SANA) as overvalued in December 2025, predicting a significant price drop. The stock subsequently fell 40%, validating the model's assessment which uses multiple valuation methodologies to determine intrinsic value. Even after the decline, InvestingPro suggests Sana Bio remains overvalued, highlighting its financial weaknesses and dependence on capital raises.
Sana Biotechnology raises $69M through ATM share sale
Sana Biotechnology has successfully raised $69 million through an "at-the-market" (ATM) offering of its common stock. The company sold 8.6 million shares at an average price of $8.01 per share under a sales agreement established in November 2023. This capital infusion will support the company's operations and ongoing research and development efforts.
Sana Biotechnology Raises $69 Million Through ATM Equity Offering
Sana Biotechnology has successfully completed an "at-the-market" (ATM) equity offering, raising approximately $69 million in gross proceeds. This financial move involved selling 8,943,285 shares of its common stock through an existing sales agreement. The additional capital is expected to support the company's ongoing operations and development pipeline.
Sana Biotechnology Shares Fall on Sale of $69 Million in Shares Through At-The-Market Facility
Sana Biotechnology (SANA) stock declined significantly after the company announced it had sold 10.9 million shares through an "at-the-market" facility, raising approximately $69.1 million. This sale, conducted via Cowen and Company, priced the shares at an average of $6.34 each. Despite the capital raise, the increased share count due to the offering negatively impacted investor sentiment.
Sana Biotechnology (SANA) sells 21.6M shares to raise about $69M
Sana Biotechnology, Inc. announced it sold 21.6 million shares of common stock, generating approximately $69 million in net proceeds. These shares were sold through an amended and restated sales agreement with TD Securities (USA) LLC, which served as the sales agent. The transaction provides the company with additional capital and increases its share count.
Sana Biotechnology | 8-K: Current report
Sana Biotechnology completed a common stock offering on May 15, 2026, selling 21,607,878 shares for net proceeds of approximately $69.0 million. This capital raise, executed via an at-the-market offering with TD Securities (USA) LLC, provides additional funding for the company's operations and development programs while minimizing shareholder dilution.
Sana Biotechnology Raises $69 Million Through Equity Offering
Sana Biotechnology (SANA) recently raised approximately $69 million by selling 21.6 million common shares through an equity offering with TD Securities (USA) LLC. This capital injection is intended to bolster the company's financial position, supporting its ongoing operations and strategic growth plans in the competitive biotechnology sector. Despite the strengthened funding outlook, TipRanks' AI Analyst "Spark" rates SANA as "Neutral" due to weak financial performance and technical price trends, partially offset by recent strategic investments and financing flexibility.
Sana Biotechnology, Inc. (SANA) Leadership & Management Team Analysis
This article provides an analysis of Sana Biotechnology, Inc.'s leadership and management team, including CEO Steve Harr's compensation, tenure, and ownership. It summarizes recent management updates, key risks such as cash runway and share price volatility, and updates on their clinical programs for type 1 diabetes and autoimmune diseases. The company is actively focusing on its immuno-engineering platforms and exploring partnerships to advance its product candidates.
Sana Biotechnology Announces Sale of Approximately $69 Million of Shares Through its At-the-Market (ATM) Facility
Sana Biotechnology, Inc. announced the sale of approximately 21.6 million shares through its at-the-market (ATM) facility, generating about $69 million in net proceeds. This, combined with a previous $25 million investment from the Mayo Clinic, brings the total capital raised to approximately $94 million, extending the company’s expected cash runway to mid-2027. The company focuses on developing engineered cells as medicines.
SANA: Progress in gene-edited islet and in vivo CAR-T therapies positions the pipeline for major milestones
Sana Biotechnology (SANA) is making significant progress in its gene-edited islet and in vivo CAR-T cell therapies. The company highlighted advancements in engineered cell therapies for Type 1 diabetes and promising preclinical CAR-T data. Key milestones for itsSC451 and SG293 programs are expected within the next year.
Sana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell Depletion in NHPs
Sana Biotechnology presented preclinical data for SG293, an in vivo CAR T cell therapy, demonstrating cell-specific delivery, robust CAR T cell generation, and deep B cell depletion in non-human primates without lymphodepleting chemotherapy. This targeted fusosome approach, which avoids off-target effects and mitigates anti-CAR immunogenicity, is planned for clinical trials for non-Hodgkin lymphoma later this year and later for B cell-mediated autoimmune diseases and multiple myeloma. The data support the potential for off-the-shelf treatment options for various blood cancers and autoimmune disorders.
A Quick Look at Today's Ratings for Sana Biotechnology(SANA.US), With a Forecast Between $7 to $16
This article provides an overview of current analyst ratings for Sana Biotechnology (SANA.US), highlighting a price target forecast ranging from $7 to $16. It is intended to offer a quick snapshot of market sentiment and expectations for the company's stock performance.
Sana Biotechnology | 10-Q: Q1 2026 Earnings Report
This document is Sana Biotechnology's 10-Q filing for its Q1 2026 earnings report. A 10-Q is a comprehensive quarterly report submitted to the U.S. Securities and Exchange Commission (SEC) by public companies. It contains unaudited financial statements, management discussion and analysis, and other relevant information about the company's performance and financial condition.
Sana Biotechnology (NasdaqGS:SANA) Stock Forecast & Analyst Predictions
Sana Biotechnology (NasdaqGS:SANA) is forecast to have declining earnings at 6.3% per annum but significant annual revenue growth of 77.8%. The company is focused on developing hypoimmune cell therapies for type 1 diabetes and B-cell mediated autoimmune diseases, with recent positive clinical data from its UP421 program and several price target reductions from analysts. Despite promising clinical developments and numerous SEC filings and announcements regarding its pipeline and executive changes, Sana faces major financial risks including a limited cash runway, expected unprofitability for the next three years, and high stock price volatility.
Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates
Sana Biotechnology, Inc. reported its first-quarter 2026 financial results, highlighting significant progress in its cell therapy programs. Key updates include a strategic collaboration with Mayo Clinic for SC451 in type 1 diabetes, advancement towards Phase 1 trials for SC451 and SG293, and positive 14-month clinical results for UP421. The company ended Q1 2026 with a cash position of $101.1 million, projecting a cash runway into 2027.
Sana Biotechnology | 10-Q: Quarterly report
This document is a Quarterly Report (Form 10-Q) filed by Sana Biotechnology. It is a standard regulatory filing providing a comprehensive overview of the company's financial performance and operational activities for the specified quarter.
Sana Biotechnology (SANA) Q1 2026 loss widens cash risk despite Mayo deal
Sana Biotechnology reported a Q1 2026 net loss of $47.2 million, an improvement from $49.4 million a year ago, primarily due to reduced research and development spending. Despite this, the company's cash reserves of $101.1 million as of March 31, 2026, are deemed insufficient to fund operations for the next 12 months, raising "substantial doubt" about its going concern ability. Post-quarter, Mayo Clinic invested $25.0 million by purchasing shares, with an option for an additional similar investment, and Sana retains an at-the-market facility for up to $150.0 million in stock sales to secure further capital.
Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates
Sana Biotechnology reported its Q1 2026 financial results, highlighting a strategic collaboration with Mayo Clinic, progress on clinical trials for SC451 and SG293, and advancements in its preclinical pipeline. The company also announced a cash position of $101.1 million, with an expected runway into 2027, and appointed Brian Piper as its new Chief Financial Officer. Financial results included a net loss of $47.2 million for the quarter.
Mayo collaboration and Q1 2026 results for Sana (NASDAQ: SANA)
Sana Biotechnology reported its Q1 2026 financial results, including a GAAP net loss of $47.2 million and a non-GAAP net loss of $38.8 million, alongside a reduced non-GAAP operating cash burn of $37.0 million. The company announced a strategic collaboration with Mayo Clinic for its SC451 type 1 diabetes program, featuring a $25.0 million equity investment from Mayo, and provided updates on its pipeline progression, expecting a cash runway into 2027. They also shared positive 14-month data from an investigator-sponsored UP421 study for type 1 diabetes without immunosuppression.
Sana: Q1 Earnings Snapshot
Sana Biotechnology Inc. (SANA) reported a first-quarter loss of $47.2 million, or 17 cents per share, which adjusted to 14 cents per share for non-recurring costs. This result surpassed Wall Street expectations, as analysts surveyed by Zacks Investment Research had predicted a loss of 15 cents per share. The Seattle-based company's earnings snapshot highlights its financial performance for the initial quarter.
Sana: Q1 Earnings Snapshot
Sana Biotechnology Inc. (SANA) reported a first-quarter loss of $47.2 million, or 17 cents per share. After adjusting for non-recurring costs, the loss per share was 14 cents, which exceeded Wall Street's expectations. Analysts surveyed by Zacks Investment Research had predicted a loss of 15 cents per share.
Rodman & Renshaw initiates Sana Biotechnology stock with buy rating
Rodman & Renshaw has initiated coverage on Sana Biotechnology (NASDAQ:SANA) with a Buy rating and a $16.00 price target, citing the company's hypoimmune platform in Type 1 Diabetes and its in vivo CAR T franchise, alongside management's track record. The company's innovative approaches aim to address significant medical needs, including eradicating the need for immunosuppression in Type 1 Diabetes and developing advanced CAR T cell generation methods. This initiation follows other recent positive developments for Sana Biotechnology, including preclinical data presentations for its SG293 product and a strategic collaboration with the Mayo Clinic for its SC451 therapy.
Earnings Flash (SANA) Sana Biotechnology, Inc. Posts Q1 Adjusted Loss $0.14 per Share, vs. FactSet Est of $-0.16
Sana Biotechnology, Inc. (SANA) announced a Q1 adjusted loss of $0.14 per share, which is better than the FactSet estimate of -$0.16 per share. The biotechnology company is focused on developing engineered cell therapies for various diseases, including type 1 diabetes, oncology, and autoimmune conditions. The article also provides recent news and stock performance data for Sana Biotechnology.
Is Sana Biotechnology’s (SANA) Options Spike Before Earnings Hinting at a Repriced Cell Therapy Story?
Sana Biotechnology (SANA) is experiencing significant pre-earnings options activity and elevated implied volatility ahead of its first-quarter earnings and a presentation at the BofA Securities Healthcare Conference. Investors are keen to see updates on the company's engineered cell therapy pipeline, including collaborations with Beam Therapeutics and Mayo Clinic. Despite zero revenue and substantial annual losses, the market activity suggests anticipation of meaningful news, though core risks like dilution and litigation remain.
Sana Biotechnology (SANA) Valuation Check As Conference Update And Partnerships Keep Investor Focus High
Sana Biotechnology (SANA) is under investor scrutiny ahead of its CEO's presentation at the BofA Securities 2026 Healthcare Conference. Despite recent share price gains, the company trades at a preferred price-to-book multiple of 6x, which is considered overvalued compared to the broader US biotech industry's average of 2.5x, especially given its projected unprofitability. Investors are weighing the potential of its pipeline against the risk of disappointing updates on clinical data, partnerships, or funding.
Sana Biotechnology (SANA) Valuation Check As Conference Update And Partnerships Keep Investor Focus High
Sana Biotechnology (SANA) is gaining investor attention ahead of its CEO's presentation at the BofA Securities 2026 Healthcare Conference. Despite recent share price gains, the stock's 6x Price to Book ratio is considered overvalued compared to the broader US biotech industry's 2.5x, given its continued unprofitability. Investors are weighing the potential of its cell engineering platforms against the risks of clinical disappointments and funding shortfalls.
Sana Biotechnology (Nasdaq:SANA) - Stock Analysis
Sana Biotechnology (Nasdaq:SANA) is a biotechnology company focused on engineered cell therapies, with a current market cap of US$1.0 billion. Despite recent positive clinical results for its type 1 diabetes treatment (HIP-modified islet cells), the company faces significant financial risks, including an unprofitable state, projected earnings decline, limited cash runway, and shareholder dilution. Analysts have a price target of US$8.57, suggesting the stock is undervalued, but acknowledge the speculative nature and volatility associated with early-stage biotech companies.
Sana CEO Steve Harr to give business update in May 12 webcast
Sana Biotechnology (NASDAQ: SANA) announced that its President and CEO, Steve Harr, will provide a business overview and company update at the BofA Securities 2026 Healthcare Conference on May 12, 2026, at 2:20 p.m. PT. The presentation will be webcast live on Sana's Investor Relations site and a replay will be available for 30 days. This update follows recent positive developments for the company, including preclinical data and a collaboration with the Mayo Clinic.
Sana Biotechnology to Present at the BofA Securities 2026 Healthcare Conference
Sana Biotechnology, Inc. announced its participation in the BofA Securities 2026 Healthcare Conference, where CEO Steve Harr will provide a business overview. The presentation, scheduled for May 12, 2026, at 2:20 p.m. PT, will be webcast on the company's Investor Relations page. A replay will be available for 30 days after the event.
A one-shot cure for diabetes? Sana Biotechnology makes its move
Sana Biotechnology has partnered with Mayo Clinic to advance SC451, a potential one-time cell therapy for Type 1 diabetes. This therapy aims to restore the body's natural ability to regulate blood sugar by transplanting engineered pancreatic islet cells that can evade the immune system. If successful, this approach could free patients from daily insulin injections and immunosuppressant drugs, offering a transformative shift from managing chronic disease to restoring cellular function.
Sana Biotechnology (NASDAQ:SANA) Shares Down 7.3% - Time to Sell?
Sana Biotechnology (NASDAQ:SANA) shares fell 7.3% on Wednesday, with trading volume significantly below average. The clinical-stage biopharma company, with a market cap of $843.7 million, has a "Moderate Buy" consensus rating from analysts, though recent price target adjustments and an earnings miss have influenced investor sentiment. Institutional investors hold a substantial portion of the company's shares.
[ARS] Sana Biotechnology, Inc. SEC Filing
This article announces an SEC filing (Form ARS) by Sana Biotechnology, Inc. (SANA) on April 24, 2026, with a neutral sentiment and low impact. It also provides an overview of Sana Biotechnology, including its stock performance rankings and recent news and SEC filings. The filing is available as a PDF document on SEC EDGAR.
Sana Biotechnology Announces Oral Presentation Highlighting
Sana Biotechnology, Inc. announced that its abstract highlighting preclinical data from SG293, a CD19-directed in vivo CAR T product candidate, has been accepted for oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting. The presentation will detail SG293's potent, safe, and cell-specific in vivo generation of CAR-T cells in NHPs, representing a differentiated approach for both oncology and autoimmune indications, potentially avoiding off-target concerns. Sana intends to explore SG293 in both B-cell cancers and B-cell mediated autoimmune diseases.
Sana Biotechnology to present preclinical CAR-T data at May meeting
Sana Biotechnology (NASDAQ:SANA) will present preclinical data for its SG293 CAR-T product candidate at the American Society of Gene & Cell Therapy Annual Meeting. The presentation will detail how SG293, a CD19-directed in vivo CAR T therapy using fusogen-based delivery, effectively generates CAR-T cells in non-human primates for treating B-cell cancers and autoimmune diseases. This follows another recent development where Sana Biotechnology announced a collaboration with the Mayo Clinic to advance SC451, an investigational cell therapy for type 1 diabetes.
Sana Biotechnology Announces Oral Presentation Highlighting
Sana Biotechnology, Inc. announced that preclinical data for its CD19-directed in vivo CAR T product candidate, SG293, has been selected for an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting. SG293, which uses Sana’s proprietary fusogen-based delivery technology, aims to provide potent and precise in vivo CAR T therapy for oncology and autoimmune indications while avoiding off-target concerns. The presentation will detail how SG293 enables cell-specific delivery to CD8+ T cells to generate CD19-directed CAR T cells.
Sana Biotech surges as Eric Jackson calls it a 100-bagger
Sana Biotech (NASDAQ:SANA) surged significantly after investor Eric Jackson described it as a potential "100-bagger" stock. This endorsement from a notable investor has likely contributed to the positive market reaction and increased investor interest in the company.
Wall Street Zen Downgrades Sana Biotechnology (NASDAQ:SANA) to Strong Sell
Wall Street Zen has downgraded Sana Biotechnology (NASDAQ:SANA) from a "sell" to a "strong sell," despite MarketBeat's consensus remaining a "Moderate Buy" with an average price target of $8.20. SANA shares experienced a 4.4% dip, opening at $3.29, after the company missed its Q1 EPS estimates, reporting ($0.16) versus a consensus of ($0.13). The clinical-stage biotech, focusing on engineered cell therapies, has seen varied analyst ratings, including upgrades from Wedbush and Bank of America, but also downgrades from Zacks Research and HC Wainwright.
Sana Biotechnology reclassifies board member to balance director classes
Sana Biotechnology (NASDAQ:SANA) announced the reclassification of Dr. Steven D. Harr's director status to balance its three board classes, effective Wednesday. Dr. Harr resigned as a Class I director and was immediately reappointed as a Class III director, with his service considered continuous. This move ensures three directors in each board class, following a period where the company's shares surged 94% over the past year despite recent pullbacks, with analysts maintaining price targets between $7 and $12.
Sana Biotechnology | DEF 14A: Definitive information statements
This article provides definitive information statements (DEF 14A) for Sana Biotechnology. The content explicitly states "Document," indicating that the document itself contains further details regarding these statements.
Sana Biotechnology | DEFA14A: Others
This article is a DEFA14A filing from Sana Biotechnology, indicating a document submission related to proxy materials. The content provided is simply "Document", suggesting the main filing details are within the attached document.
Sana Biotechnology reclassifies board member to balance director classes
Sana Biotechnology (NASDAQ:SANA) reclassified board member Steven D. Harr, M.D., to balance its three director classes, ensuring an equal distribution of three directors per class. This governance change, made to comply with the company's certificate of incorporation, maintains Dr. Harr's continuous service despite the reclassification from a Class I to a Class III director. The company, valued at $944 million, has seen significant stock performance and is also progressing with its SC451 pancreatic islet cell therapy through a collaboration with the Mayo Clinic.
Sana Biotechnology Rebalances Board Classes With Director Shift
Sana Biotechnology (SANA) rebalanced its Board of Directors on April 22, 2026, by reclassifying Director Steven D. Harr from a Class I to a Class III director. This administrative change ensures an equal distribution of directors across the three classes, aligning with the company's governance structure, and did not interrupt Dr. Harr's board service. Analysts currently rate SANA as a Buy with a $7.00 price target, though Spark's AI Analyst gives a Neutral rating due to weak financial fundamentals despite constructive corporate events.
Sana Biotechnology (SANA) details 2026 virtual meeting, board elections and EY ratification
Sana Biotechnology, Inc. (SANA) has released details for its virtual 2026 annual stockholder meeting, scheduled for June 4, 2026. Stockholders will vote on the re-election of three Class II directors—Hans E. Bishop, Robert Nelsen, and Alise S. Reicin, M.D.—and the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The Board unanimously recommends voting "FOR" all proposals.
Sana Biotechnology (SANA) Is Up 6.3% After Mayo-Backed SC451 Diabetes Cell Therapy Collaboration - What's Changed
Sana Biotechnology has seen a 6.3% rise following a collaboration with Mayo Clinic to advance SC451, a cell therapy for type 1 diabetes. Mayo Clinic will provide clinical expertise and an initial US$25 million equity investment, with an option for more funding. This partnership aims to standardize protocols for SC451, reinforcing Sana's development efforts despite ongoing losses and high cash burn, though financial and execution risks remain.
Sana Biotechnology (SANA) Valuation Check After Mayo Clinic SC451 Collaboration And Recent Share Price Swing
Sana Biotechnology (SANA) has partnered with Mayo Clinic to advance its SC451 therapy for type 1 diabetes, which has resulted in a recent share price rally. Despite a 22.8% 30-day return, the year-to-date performance remains negative, prompting a valuation check. The company's Price-to-Book ratio of 6.5x is in line with peers but significantly higher than the broader US biotechs industry average, indicating that investors are valuing Sana's net assets at a premium, though it is still pre-revenue and loss-making.
Sana Biotechnology (SANA) Is Up 6.3% After Mayo-Backed SC451 Diabetes Cell Therapy Collaboration - What's Changed
Sana Biotechnology has seen a 6.3% increase following a collaboration with Mayo Clinic to advance SC451, a cell therapy for type 1 diabetes. Mayo Clinic is investing US$25 million and providing clinical expertise, which strengthens Sana's position despite ongoing losses and funding needs. While this partnership addresses some immediate concerns regarding diabetes development and trial execution, Sana Biotechnology still faces significant issues like high cash burn and unproven commercial viability.
Sana Biotechnology (SANA) Valuation Check After Mayo Clinic SC451 Collaboration And Recent Share Price Swing
Sana Biotechnology (SANA) is being re-evaluated after its collaboration with Mayo Clinic for SC451, a hypoimmune-modified pancreatic islet cell therapy for type 1 diabetes, which included an equity investment. Despite a recent 22.8% 30-day share price return and a significant 1-year total return, the stock remains down year-to-date. The company trades at a Price-to-Book (P/B) ratio of 6.5x, comparable to its peers but significantly higher than the broader US biotech industry average, indicating investors are assigning a higher value to its net assets despite no current revenue and a net loss of $244.166 million.
Wedbush Lifts PT on Sana Biotechnology (SANA) to $7 From $6
Wedbush has increased its price target for Sana Biotechnology (SANA) to $7 from $6, reaffirming its Outperform rating. This decision follows Sana's collaboration with Mayo Clinic to develop type 1 diabetes candidate SC451, which includes an initial $25 million investment from Mayo Clinic for 7.5 million shares, extending Sana's cash runway into 2027. Sana Biotechnology focuses on engineered cell therapies for various conditions, including diabetes and oncology.
10 Stocks Under $5 with Huge Upside Potential
This article highlights Sana Biotechnology, Inc. (SANA) as a top stock under $5 with significant upside potential. Wedbush recently raised its price target to $7 from $6 and reaffirmed an Outperform rating following Sana's collaboration with the Mayo Clinic for developing therapies for type 1 diabetes, which includes an investment of up to $50 million. Sana Biotechnology specializes in engineered cell therapies for various conditions, extending its cash runway into 2027.
